Cardiac allograft vasculopathy: The achilles' heel of long-term survival after cardiac transplantation

Current Atherosclerosis Reports

Volumn 8, Issue 2, 2006, Pages 119-130

  Dhaliwal, Amandeep ^b   Thohan, Vinay ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DOBUTAMINE; EVEROLIMUS; FLUINDOSTATIN; GAMMA INTERFERON; GANCICLOVIR; HLA ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PRAVASTATIN; PREDNISONE; RAPAMYCIN; RENIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGRAPHY; CARDIAC ALLOGRAFT VASCULOPATHY; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY STENT; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DONOR; ECHOCARDIOGRAPHY; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INTRAVASCULAR ULTRASOUND; LIFE EXPECTANCY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE PERIOD; RECIPIENT; REPERFUSION INJURY; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SCREENING TEST; SURVIVAL RATE; UNITED STATES;

CORONARY DISEASE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; INCIDENCE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 33645081487     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0049-1     Document Type: Review

References (117)

1. Schroeder JS, Hunt S: Cardiac transplantation. Update 1987. JAMA 1987, 258:2142-2155.
2. United Network for Organ Sharing: http://www.unos.org. Accessed November 15, 2005.
3. Eisen HJ, Tuzcu EM, Dorent R, et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003, 349:847-858.
4. Trulock EP, Edwards LB, Taylor DO, et al.: Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Lung and Heart-Lung Transplant Report - 2005. J Heart Lung Transplant 2005, 24:956-967.
5. Bieber CP, Stinson EB, Shumway NE, et al.: Cardiac transplantation in man. VII. Cardiac allograft pathology. Circulation 1970, 41:753-772.
6. Gao SZ, Schroeder JS, Alderman EL, et al.: Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation 1989, 80(Suppl 3):100-105.
7. Olivari MT, Homans DC, Wilson RF, et al.: Coronary artery disease in cardiac transplant patients receiving triple drug immunosuppressive therapy. Circulation 1989, 80:111-115.
8. Uretsky BF, Murali S, Reddy PS, et al.: Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987, 76:827-834.
9. McGiffin DC, Savunen T, Kirklin JK, et al.: Cardiac transplant coronary artery disease. A multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thorac Cardiovasc Surg 1995, 109:1081-1088.
10. Yeung AC, Davis SF, Hauptmann PJ, et al.: Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Ransplant 1995, 14:S215-S220.
11. Rickenbacher PR, Pinto FJ, Chenzbraun A, et al.: Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995, 25:171-177.
12. Keogh AM, Valantine HA, Hunt SA, et al.: Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 1992, 11:892-901.
13. Uretsky BF, Kormos RL, Zerbe TR, et al.: Cardiac events after transplantation: incidence and predictive value of coronary arteriopathy. J Heart Lung Transplant 1992, 11:S45-S51.
14. Gao SZ, Hunt SA, Schroeder JS, et al.: Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol 1996, 28:673-679.
15. Alexis JD, Pyo RT, Chereshnev I: Immunologic factors in transplant arteriopathy. Mt Sinai J Med 2003, 70:191-196.
16. Balantyne CM: Statins after cardiac transplantation: which statin, what dose and how low should we go? J Heart Lung Transplant 2000, 19:515-517.
17. Kapadia SR, Nissen SE, Ziada KM, et al.: Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation 1998, 98:2672-2678.
18. Jimenez J, Kapadia SR, Yamani MH, et al.: Cellular rejection and rate of progression of transplant vasculopathy: A 3-year serial intravascular ultrasound study. J Heart Lung Transplant 2001, 20:393-398.
19. Fang JC, Kinlay S, Beltrame J, et al.: Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002, 359:1108-1113.
20. Tanaka M, Mokhtari GK, Terry RD, et al.: Overexpression of human copper/zinc superoxide dismutase (SODL) suppresses ischemia-reperfusion injury and subsequent development of graft coronary artery disease in murine cardiac grafts. Circulation 2004, 110(11 Suppl 1): II200-II206.
21. Murata S, Miniati DN, Kown MH, et al.: Superoxide dismutase mimetic m40401 reduces ischemia-reperfusion injury and graft coronary artery disease in rodent cardiac allografts. Transplantation 2004, 78:1166-1171.
22. Ferri C, Properzi G, Tomassoni G, et al.: Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. Circulation 2002, 105:1768-1771.
23. Laberrere CA, Nelson DR, Park JW: Pathologic markers of allograft vasculopathy: insight into the pathophysiology of allograft chronic rejection. Curr Opin Cardiol 2001, 16:110-117.
24. Labarrere CA, Nelson DR, Cox CJ, et al.: Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 2000, 284:457-464.
25. Laberrere CA, Pitts D, Nelson DR, Faulk WP: Vascular tissue plasminogen activator and the development of coronary artery disease in heart transplant recipients. N Engl J Med 1995, 333:1111-1116.
26. Garvin MR, Labinaz M, Pels K, et al.: Arterial expression of the plasminogen activator system early after cardiac transplantation. Cardiovasc Res 1997, 35:241-249.
27. Wong CK, Ganz P, Miller L, et al.: Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective ultrasound study. J Heart Lung Transplant 2001, 20:385-392.
28. Lim TT, Liang DH, Botas J, et al.: Role of compensatory enlargement and shrinkage in transplant coronary artery disease: serial intravascular ultrasound study. Circulation 1997, 95:885-859.
29. Pethig K, Heublein B, Meliss RR, et al.: Volumetric remodeling of the proximal left coronary artery: early versus late after heart transplantation. J Am Coll Cardiol 1999, 34:197-203.
30. Tsutsui H, Ziada KM, Schoenhagen P, et al.: Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5 year serial intravascular ultrasound study. Circulation 2001, 104:653-657.
31. Vassalli G, Gallino A, Weis M, von Scheidt W, et al.: Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003, 24:1180-1188.
32. Caforio AL,Tona F, Fortina AB, et al.: Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplantation 2004, 4:962-970.
33. Vamvakopoulos J, Hayry P: Cytomegalovirus and transplant arteriopathy: evidence for a link is mounting but the jury is still out. Transplantation 2003, 75:742-743.
34. Opelz G, Wujciak T: The influence of HLA compatibility on graft survival. Collaborative Transplant Study. N Engl J Med 1994, 330:816-819.
35. Gullestad L, Simonsen S, Ueland T, et al.: Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol 1999, 8:999-1003.
36. Labarrere CA, Nelson DR, Miller SJ, et al.: Value of serum-soluble intercellular adhesion molecules for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure. Circulation 2000, 102:1549-1555.
37. Ballantyne CM, Mainolfi EA, Young JB, et al.: Relationship of increased levels of circulating intercellular adhesion molecule 1I after heart transplantation to rejection: human leukocyte antigen mismatch and survival. J Heart Lung Transplant 1994, 13:597-603.
38. Vasilescu ER, Ho EK, de la Torre L, et al.: Anti-HLA antibodies in heart transplantation. Transplant Immunol 2004, 12:177-183.
39. Petrossian GA, Nichols AB, Marboe CC, et al.: Relationship between survival and development of coronary artery disease and anti-HLA antibodies after Cardiac Transplantation. Circulation 1989, 80:III122-III125.
40. Reed EF, Hong B, Ho E, et al.: Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Ransplantation 1996, 61:566-572.
41. Michaels PJ, Espejo ML, Kobashigawa J, et al.: Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003, 22:58-69.
42. Rose ML: Role of antibodies in transplant-associated cardiac allograft vasculopathy. Z Kardiol 2000, 89 (Suppl 9):IX/11-IX15.
43. Jurcevic S, Ainsworth ME, Pomerance A, et al.: Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71:886-892.
44. Collins AD, Ationu A: The role of anti-endothelial antibodies in the immunopathogenesis of transplant associated coronary artery disease. Int J Mol Med 1998, 1:439-452.
45. Faulk WP, Rose M, Meroni PL, et al.: Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 1999, 60:826-832.
46. Grattan MT, Moreno-Cabral CE, Starnes VA, et al.: Cytomegalovirus infection is associated with cardiac allograft rejection and artherosclerosis. JAMA 1989, 261:3561.
47. Potena L, Grigioni F, Ortolani P, et al.: Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003, 75:839-843.
48. Petrakopoulou P, Kubrich M, Pehlivanli S, et al.: Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004, 110(11 Suppl 1):II207-II212.
49. Weis M, Kledal TN, Lin KY, et al.: Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004, 109:500-505.
50. Shirali GS, Ni J, Chinnock RE, et al.: Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001, 244:1498-1503.
51. Yousufuddin M, Yamani MH: The renin-angiotensin hypothesis for the pathogenesis of cardiac allograft vasculopathy. Int J Cardiol 2004, 95:123-127.
52. Richter MH, Richter HR, Olbrich HG, et al.: Two good reasons for an angiotensin-II type 1 receptor blockade with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy. Transplant Int 2003, 16:26-32.
53. Kobayashi J, Crawford S, Backer CL, et al.: Captopril reduces graft coronary artery disease in a rat heterotropic transplant model. Circulation 1993, 88:286-290.
54. Furukawa Y, Matsumori A, Hirozane T, et al.: Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserve graft status in murine model. A comparative study with captopril. Circulation 1996, 93:333-339.
55. Crawford SE, Mavroudis C, Backer CL, et al.: Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels. J Heart Lung Transplant 2004, 23:666-673.
56. Ventura HO, Mehra MR: C-Reactive protein and cardiac allograft vasculopathy. Is inflammation the critical link? J Am Coll Cardiol 2003, 42:483-485.
57. Hognestad A, Endresen K, Wergeland R, et al.: Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 2003, 42:477-482.
58. Labarrere CA, Lee JB, Nelson DR, et al.: C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 2002, 360:1462-1467.
59. Calabro P, Willerson JT, Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003, 108:1930-1932.
60. Hollenberg SM, Klein LW, Parrillo JE, et al.: Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001, 104:3091-3096.
61. Andriambeloson E, Pally C, Hengerer B, et al.: Transplantation-induced endothelial dysfunction as studied in rat aorta allografts. Transplantation 2001, 72:1881-1889.
62. Hollenberg SM, Klein LW, Parrillo JE, et al.: Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2004, 23:265-271.
63. Davis SF, Yeung AC, Meredith IT, et al.: Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996, 93:457-462.
64. Labarrere CA, Nelson DR, Faulk WP: Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 1997, 278:1169-1175.
65. Methe H, Zimmer E, Grimm R, et al.: Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004, 78:1324-1331.
66. Shi C, Lee WS, He Q, Zhang D, et al.: Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996, 93:4051-4056.
67. Shi C, Feinberg MW, Zhang D, et al.: Donor MHC and adhesion molecules in transplant arteriosclerosis. J Clin Invest 1999, 103:469-474.
68. Dietrich H, Hu Y, Zou Y, et al.: Mouse model of transplant arteriosclerosis: role of intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol 2000, 20:343-352.
69. Raisanen-Sokolowski A, Glysing-Jensen T, Koglin J, et al.: Reduced transplant arterioscleross in murine cardiac allografts placed in interferon gamma knockout recipients. Am J Pathol 1998, 152:359-365.
70. Koglin J, Glysing-Jensen T, Gadiraju S, et al.: Attenuated cardiac allograft vasculopathy in mice with targeted depletion of transcription factor stat 4. Circulation 2000, 101:1034-1039.
71. Gao W, Topham PS, King JA, et al.: Targeting of the chemokine receptor CCR 1 suppresses the development of acute and chronic cardiac allograft rejection. J Clin Invest 2000, 105:35-44.
72. Gao W, Faia KL, Csizmadia V, et al.: Beneficial effects of targeting CCR5 in ailograft recipients. Transplantation 2001, 72:1199-1205.
73. Raisanen-Sokolowski, Glysing-Jensen T, Russel ME: Leukocyte suppressing influences of interleukin 10 in cardiac allografts: insights from IL-10 knockout mice. Am J Pathol 1998, 153:1491-1500.
74. Tanaka M, Terry RD, Mokhtari GK, et al.: Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Circulation 2004, 110 (11 Suppl 1):II194-II199.
75. Ventura HO, White CJ, Jain SP, et al.: Assessment of intracoronary morphology in cardiac transplant recipients by angioscopy and intravascular ultrasound. Am J Cardiol 1993, 72:805-809.
76. St Goat FG, Pinto FJ, Alderman EL, et al.: Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. Circulation 1992, 85:979-987.
77. Rickenbacher PR, Pinto FJ, Lewis NP, et al.: Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995, 92:3445-3452.
78. Rickenbacher PR, Pinto FJ, Chenzbraun A, et al.: Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995, 25:171-177.
79. Mohiaddin RH, Bogren HG, Lazim F, et al.: Magnetic resonance coronary angiography in heart transplant recipients. Coron Artery Dis 1996, 7:591-597.
80. Muehling OM, Wilke NM, Panse P, et al.: Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging. J Am Coll Cardiol 2003, 42:1054-1060.
81. Knollmann RD, Bocksch W, Spiegelsberger S, et al.: Electron bean computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation 2000, 101:2078-2082.
82. Ludman PF, Lazem F, Barbir M, et al.: Incidence and clinical relevance of coronary calcification detection by electron beam computed tomography in heart transplant recipients. Eur Heart J 1999, 20:303-308.
83. Ratliff NB, Jorgensen CR, Gobel FL, et al.: Lack of usefulness of electron beam computed tomography for detecting coronary allograft vasculopathy. Am J Cardiol 2004, 93:202-206.
84. Bae KT, Hong C, Takahashi N, et al.: Multi-detector ro computed tomographic angiography in pediatric heart transplant recipients: Initial observations. Transplantation 2004, 77:599-602.
85. Spes CH, Mudra H, Schnaack SD, et al.: Dobutamine stress echocardiography for noninvasive diagnosis of cardiac allograft vasculopathy: a comparison with angiography and intravascular ultrasound. Am J Cardiol 1996, 78:168 -174.
86. Spes CH, Klauss V, Mudra H, et al.: Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and intravascular ultrasound. Circulation 1999, 100:509-515.
87. Bacal F, Moreira L, Souza G, et al.: Dobutamine stress echocardiography predicts cardiac events or death in asymptomatic patients long-term after heart transplantation: 4-year prospective evaluation. J Heart Lung Transplant 2004, 23:1238-1244.
88. Kobashigawa JA, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
89. Wenke K, Meiser B, Thiery J, et al.: Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997, 96:1398-1402.
90. Wenke K, Meiser B, Thiery J, et al.: Simvastatin initiated early after heart transplantation. 8 year prospective experience. Circulation 2003, 107:93-97.
91. Mehra MR, Uber PA, Vivekananthan K, et al.: Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection. J Am Coll Cardiol 2002, 40:1609-1614.
92. Keogh A, Macdonald P, Kaan A, et al.: Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000, 19:529-537.
93. Wu AH, Ballantyne CM, Short BC, et al.: Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol 2005, 95:367-372.
94. Valantine HA, Gao SZ, Menon SG, et al.: Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999, 100:61-66.
95. Valantine HA, Luikart H, Doyle R, et al.: Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001, 72:1647-1652.
96. Randovancevic B, Vrtovec B: Sirolimus therapy in cardiac transplantation. Transplantation Proc 2003, 35 (Suppl 3A): 171S-176S.
97. Mancini D, Pinney S, Burkhoff D, et al.: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48-53.
98. Keogh A, Richardson M, Ruygrok P, et al.: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004, 110:2694-2700.
99. Eisen HJ, Tuzcu EM, Dorent R, et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003, 349:847-858.
100. Halle AA 3rd, DiSciascio G, Massin EK, et al.: Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995, 26:120-128.
101. Benza RL, Zoghbi GJ, Tallaj J, et al.: Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol 2004, 43:1973-1981.
102. Fedak PW, Rao V, Verma S, et al.: Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. J Thorac Cardiovasc Surg 2005, 129:407-415.
103. Wang CY, Aronson I, Takuma S, et al.: CAMP pulse during preservation inhibits the late development of cardiac isograft and allograft vasculopathy. Circ Res 2000, 86:982-988.
104. Twata A, Sai S, Moore M, et al.: Gene therapy of transplant arteriopathy by liposome-mediated transfection of endothelial nitric oxide synthase. J Heart Lung Transplant 2000, 19:1017-1028.
105. Scholl FG, Sen L, Drinkwater DC, et al.: Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis. J Heart Lung Transplant 2001, 20:322-329.
106. Suzuki J, Isobe M, Yamazaki S, et al.: Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecules and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. J Heart Lung Transplant 1997, 16:1141-1148.
107. Orosz CG, Ohye RG, Pelletier RP, et al.: Treatment with anti-vascular cell adhesion molecule 1 monoclonal antibody induces long-term murine cardiac allograft acceptance. Transplantation 1993, 56:453-460.
108. Russell PS, Chase CM, Winn HJ, et al.: Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-gamma. Transplantation 1994, 57:1367-1371.
109. Wang CY, Mazer SP, Minamoto K, et al.: Suppression of murine cardiac allograft arteriopathy by long term blockade of CD40-CD154 interactions. Circulation 2002, 105:1609-1614.
110. Saiura A, Sata M, Hiasa K, et al.: Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler Thromb Vasc Biol 2004, 24:1886-1890.
111. Yamoura K, Ito K, Tsukioka K, et al.: Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Circulation 2004, 110:1650-1657.
112. El-Sawy T, Belperio JA, Strieter RM, et al.: Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 2005, 112:320-331.
113. Nykanen AI, Krebs R, Tikkanen JM, et al.: Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. Transplantation 2005, 79:182-189.
114. Nykanen AI, Krebs R, Saaristo A, et al.: Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003, 107:1308-1314.
115. Isobe M, Suzuki JI, Morishita R, et al.: Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997, 3:900-903.
116. Kawauchi M, Suzuki J, Morishita R, et al.: Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 2000, 87:1063-1068.
117. Tsukioka K, Suzuki J, Fujimori M, et al.: Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc Res 2002, 56:472-478.